FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to therapy and pulmonology, and may be used for the purpose of the pharmacological correction of lung tissue disorders developed after the cytostatics have been prescribed. For this purpose, 3 hours after having prescribed a cytostatic, and then 1, 3, 7, 10 days thereafter, the neuroleptic agent haloperidol is administered into laboratory animals; besides every time 1 hour before administering haloperidol, hyaluronidase immobilised on polyethylene is introduced intranasally.
EFFECT: method enables the higher therapeutic effectiveness in the lung tissue disorders after the action of the cytostatics due to the manifested anti-inflammatory effect with the improved biological activity and lower toxicity and immunogenicity.
1 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING PULMONARY FIBROSIS | 2012 |
|
RU2494470C1 |
| AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTION IN PULMONARY TISSUE, AND CYTOSTATIC ACTION | 2013 |
|
RU2530651C1 |
| MEANS FOR PNEUMOFIBROSIS PREVENTION AND TREATMENT AND METHOD FOR ITS PRODUCTION | 2016 |
|
RU2646810C1 |
| PREPARATION PREVENTING DEVELOPMENT OF ABNORMALITIES IN LUNG TISSUE UNDER CYTOSTATIC IMPACT | 2011 |
|
RU2455991C1 |
| AGENT POSSESSING ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTION IN PULMONARY TISSUE, AND CYTOSTATIC ACTION | 2012 |
|
RU2479312C1 |
| AGENT PREVENTING DEVELOPING DISORDERS IN PULMONARY TISSUE AND BLOOD SYSTEM ACCOMPANYING CYTOSTATIC ACTION | 2011 |
|
RU2464983C1 |
| DRUG POSSESSING REGENERATIVE ACTIVITY | 2011 |
|
RU2480236C1 |
| AGENT FOR CORRECTING PULMONARY TISSUE DISORDERS UNDER CYTOSTATIC EXPOSURE | 2013 |
|
RU2554776C1 |
| METHOD FOR PRODUCING AND INDUCING TARGETED DIFFERENTIATION OF PULMONARY PLURIPOTENT CELL CULTURE | 2013 |
|
RU2554843C2 |
| METHOD FOR SIMULATING A COMBINED PATHOLOGY OF METABOLIC SYNDROME AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2019 |
|
RU2714679C1 |
